Skip to Content

Intarcia Board of Directors

Board Members


Kurt Graves – Chairman, President and CEO, Intarcia Therapeutics, Inc.

Mr. Graves has been Chairman, President and CEO of Intarcia since April 2012, having previously served solely as Executive Chairman of the company since August 2010, and as Acting CEO since October 2011. During his time at Intarcia, his influence on the Company’s vision, purpose and values has transformed not only its business goals, but also how it goes about its business. Since he joined, Intarcia successfully raised more than $1 billion in capital through very creative financings and strategic partnerships. Mr. Graves was named the 2015 EY Entrepreneur of the Year in New England, and Intarcia was cited as a “Unicorn” company worth watching in a cover story of Fortune Magazine, and a 2015 “Disruptor 50” company by CNBC. Mr. Graves is a global industry leader with more than twenty years of U.S. and global general management experience at top-tier U.S. and European based pharmaceutical and biotech companies. He has successfully built and managed several of the largest multi-billion dollar franchises in the industry and developed and launched more than 10 blockbuster brands in a broad range of general medicine, specialty and orphan disease areas. In addition to driving dynamic top and bottom-line growth in large global pharmaceutical companies, Mr. Graves also played a key leadership role in building two highly successful early stage companies: Astra Merck Pharmaceuticals and Vertex Pharmaceuticals. Prior to joining Intarcia, Mr. Graves was EVP, Chief Commercial Officer, and Head of Corporate and Strategic Development at Vertex Pharmaceuticals. Before his tenure at Vertex, he spent nearly ten years at Novartis Pharmaceuticals, most recently on the Executive Committee as Global Head of the General Medicines Business Unit & Chief Marketing Officer for the Pharmaceuticals division. Prior to Novartis, Mr. Graves held several commercial and general management positions at Merck and Astra Merck/Astra Pharmaceuticals where he spent most of his time leading the GI Business Unit responsible for Prilosec® and Nexium®. In addition to his current responsibility at Intarcia, Mr. Graves serves as Chairman of the Board of Radius® Health, Inc. (RDUS), and as a Director at Achillion Pharmaceuticals (ACHN), and Seres Therapeutics (MCRB). Mr. Graves earned his B.S. in Biology from Hillsdale College and has attended numerous executive leadership programs at Harvard, Wharton School of Management and University of Michigan.


Bryan Roberts, Ph.D. – Director

Bryan Roberts joined Venrock, a venture capital investment firm, in 1997, where he serves as partner. From 1989 to 1992, Dr. Roberts worked in the corporate finance department of Kidder, Peabody & Co., a brokerage company. Dr. Roberts is the chairman of Ironwood Pharmaceuticals and serves on the board of directors of ZELTIQ as well as on the board of several other private companies, and he has previously served on the board of directors of athenahealth, Inc., XenoPort, Inc. and Sirna Therapeutics, Inc. He received a B.A. from Dartmouth College and a Ph.D. in chemistry and chemical biology from Harvard University.


Gino Santini – Director

Gino Santini is a globally respected pharmaceutical executive, having spent nearly three decades at Eli Lilly and Company where he served in a number of key roles, including as a member of their Executive Committee. His distinguished career began when he joined Lilly as a Financial Planning Associate in Italy in 1983. He went on to serve in financial and marketing roles in Italy and Indianapolis, and also served as Pharmaceutical Director in Belgium, General Manager in Mexico City, Area Director of Latin America, President of Lilly’s women’s health business, and President of U.S. Operations, before ascending to Senior Vice President of Corporate Strategy and Business Development. In this final role, Mr. Santini led corporate strategy and long-range planning, M&A, new product licensing, innovative financing of internal development projects, and the expansion of Lilly Ventures in the U.S. and China. In addition to Intarcia, Mr. Santini serves on the Boards of Directors of several biopharmaceutical companies and an Italian financial holding company of businesses in the sugar, food, mechanical, and packaging sectors. He serves as an Associate Member of the Board of the National Association of Chain Drug Stores, and previously served as Chairman of the Board of the National Pharmaceutical Council, and as Chairman of the Board of Noble of Indiana, a non-profit agency that serves people with developmental disabilities. He is also a former Director of the United Way, and a former Member of the Executive Committee and Board of the Indianapolis Chamber of Commerce. Fluent in four languages, Mr. Santini holds an undergraduate degree in mechanical engineering from the University of Bologna and an MBA from the Simon School of Business, University of Rochester.


Nancy Thornberry – Director

Nancy Thornberry became a member of the Intarcia Board of Directors in December 2013. Currently, she is the CEO of Kallyope, a biotechnology company. Nancy is a highly regarded expert in pharmaceutical R&D, strategy and portfolio management and has been involved in scientific innovation in diverse areas, which paved the way for significant breakthroughs. This took place during her illustrious 34-year career at Merck Research Laboratories, where she began in 1979 as a Biochemist, and steadily assumed positions of increasing responsibility – distinguishing herself along the way with numerous and significant achievements. Those achievements came early as Nancy provided enzymology support to the angiotensin converting enzyme (ACE) inhibitor project for the treatment of hypertension, and multiple other targets. Her accomplishments also include the identification of the first caspase, interleukin-1β converting enzyme (ICE/caspase-1), and contributions to the discovery of the target of ezetimibe, the active ingredient in ZETIA™. Most notably, she co-led the team that discovered Januvia™ (sitagliptin) in 2001, which is currently the #1 branded oral agent for the treatment of type 2 diabetes, and the largest selling product in Merck history. In 2011 Nancy became SVP and Franchise Head of Diabetes and Endocrinology for Merck Research Laboratories. Also in 2011 Nancy was honored with the PhRMA Discoverers Award. In addition to her prolific publishing record, Nancy has guest lectured at prestigious venues, as well as chaired many key scientific and medical sessions.


Patrick Conway, MD – Director

Dr. Patrick Conway just recently became the President and CEO of Blue Cross Blue Shield of North Carolina. Prior to this he served as the Chief Medical Officer, Deputy Administrator for Innovation and Quality and Director of the Center for Medicare & Medicaid Innovation for the Centers of Medicare and Medicaid Services. There, he was responsible for overseeing the quality of care, innovation and new payment models for the programs that serve the over 140 million Americans for access to health care services through Medicare, Medicaid, the Children’s Health Insurance Program, and the Health Insurance Marketplace. The CMS Innovation Center he led had a budget of $10 billion over 10 years. He was instrumental in helping lead the country to these value-based and outcomes-based care systems. He is a former White House Fellow and a Robert Wood Johnson Clinical Scholar. Dr. Conway completed his pediatrics residency at Harvard Medical School's Children's Hospital Boston, graduated with High Honors from Baylor College of Medicine, and graduated summa cum laude from Texas A&M University.


Jay S. Skyler, MD, MACP – Director

Dr. Jay Skyler currently serves as a Professor of Medicine, Pediatrics and Psychology in the Division of Endocrinology Diabetes & Metabolism at the Leonard M. Miller School of Medicine at the University of Miami, where he has also held a number of key leadership roles in the clinical and drug development setting. He has played a key global leadership role in advancing the science and treatments of diabetes over the last five decades, where his own research has also focused on improving the care of type 1 diabetes through meticulous glycemic control, psychosocial and behavioral support and immune intervention. From 1993 until 2015, he was Chairman of the National Institute of Health-sponsored Diabetes Prevention Trial - Type 1 (DPT-1) and its successor Type 1 Diabetes TrialNet, a nationwide network conducting clinical trials to interdict type 1 diabetes. Dr. Skyler has also held many positions at the American Diabetes Association (ADA), including President and member of the Board of Directors. He was founding Editor-in-Chief of Diabetes Care (an ADA publication), founding Scientific Editor of the International Diabetes Monitor, and currently is Senior Editor of Diabetes Technology & Therapeutics. He has served on the Board of Directors for multiple private and public companies including MiniMed, Amylin, Dexcom, Inc. DXCM and Moerae Matrix, Dr. Skyler has been author, editor, or co-editor of 21 books and has written nearly 500 articles. Dr. Skyler is a graduate of Pennsylvania State University and Jefferson Medical College, and did his postgraduate training in internal medicine and in endocrinology & metabolism at Duke University Medical Center.


The Honorable Bob Kerrey – Director

Former Senator Bob Kerrey, who represented Nebraska as a United States Senator from 1989-2001 and as its 35th governor, serves as the managing director at Allen & Company, a small investment banking firm in New York City. He is also the executive chairman of the Minerva Project, a for-profit educational organization that provides technology, infrastructure and support services for the Minerva Schools and Keck Graduate Institute. Previously for 10 years, Kerrey served as the President of The New School, a small private university in New York City, during which the university doubled its endowment and experienced growth in enrollment, faculty, scholarship funding, capital projects, research and international engagement. Since concluding his service as a Senator, he continues to serve on key committees including the 9/11 Commission as well as the Iraq and Afghanistan Veterans Association. Kerrey served three years as a Navy SEAL in the U.S. Navy and is a Medal of Honor recipient. He earned his B.S. in Pharmacy from the University of Nebraska.

Back to top